sameAs
P129
P3781
Tofacitinib Combined With Chidamide in R/R ENKTCLOral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)CP-690,550 Pharmacokinetics In Healthy Chinese SubjectsLong-Term Study Of CP-690,550 In Subjects With Ulcerative ColitisA Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's DiseaseA Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative ColitisLong-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic ArthritisA Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative ColitisA Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative ColitisTofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy VolunteersXeljanz Special Investigation for Long-term Use in UC PatientsTofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center StudySafety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical TrialSafety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic ArthritisJAK Inhibition to Prevent Ventilator-induced Diaphragm DysfunctionIdentify Predictors That Distinguish Between Tofacitinib Responders and Non-responders Based on Genotype and Cellular and Molecular Profiles From Pinch Biopsies, Blood and Stool SamplesA 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant PatientsEfficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic ArthritisPatient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life ConditionsPharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or PlaceboA Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque PsoriasisRisk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in BangladeshEfficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis PatientsObservational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid ArthritisA Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIAOpen-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma AnnulareEvaluation of Pain Sensitization in Rheumatoid Arthritis: Analysis on a Cohort of Tofacitinib Treated PatientsEffectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia AreataTofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent SarcoidosisExamination of Efficacy and Safety of Baricitinib in RA PatientsRheumatoid Arthritis Satisfaction Outcome ResearchShingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on TofacitinibTofacitinib in Down SyndromeA Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A DayEffects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung DiseaseEfficiency of Methotrexate and Tofacitinib in Mild and Moderate PatientsTOFAcitinib in SARS-CoV2 Pneumonia
P4844
Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitorsLack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.Novel small-molecular therapeutics for rheumatoid arthritis.Tofacitinib for the treatment of rheumatoid arthritis.Risk of tuberculosis reactivation with tofacitinib (CP-690550).Kinase inhibitors: a new class of antirheumatic drugsTargeting JAK3 in kidney transplantation: current status and future options.[Janus kinase inhibitors].Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.Tofacitinib or Adalimumab versus Placebo in Rheumatoid ArthritisA phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate aloneIn vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis[Anti-rheumatic effect of JAK-inhibitors]Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritisJAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL productionTofacitinib for the treatment of moderate to severe rheumatoid arthritisPharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipientsPhase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugsTofacitinib in active ulcerative colitis
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Tofacitinib
@de
Tofacitinib
@sh
Tofacitinib
@sr
tofacitinib
@en
tofacitinib
@fr
tofacitinib
@nn
tofacitinib
@pl
xeljanz
@es
توفاسيتينيب
@ar
توفاسیتینیب
@fa
type
label
Tofacitinib
@de
Tofacitinib
@sh
Tofacitinib
@sr
tofacitinib
@en
tofacitinib
@fr
tofacitinib
@nn
tofacitinib
@pl
xeljanz
@es
توفاسيتينيب
@ar
توفاسیتینیب
@fa
altLabel
CP-690,550
@en
CP-690550
@en
Xeljanz®
@en
tasocitinib
@en
tasocitinib
@nn
託法替尼
@zh
prefLabel
Tofacitinib
@de
Tofacitinib
@sh
Tofacitinib
@sr
tofacitinib
@en
tofacitinib
@fr
tofacitinib
@nn
tofacitinib
@pl
xeljanz
@es
توفاسيتينيب
@ar
توفاسیتینیب
@fa